All In MedTech

Device Trial Radar · NCT06491771

A Cryotherapy With Tranexamic Acid Versus Normal Saline in the Treatment of Melasma

A Randomized Split-face Study of a Precision Cryotherapy Via Boosting Mode Combined With Tranexamic Acid Versus Normal Saline in the Treatment of Melasma

Last checked: Nov 19, 2026Latest source record: Jul 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

18

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

Feb 1, 2025

Study completion Jul 1, 2025

Sponsor

Lead sponsor
Mahidol UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 9, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 25 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aimed to evaluate the effectiveness of a precision cryotherapy via boosting mode combined with tranexamic acid versus normal saline in the treatment of melasma. Eighteen patients aged 25 to 60 years diagnosed with epidermal-typed melasma sized equal to or more than 2 cm on both cheeks were included. The patients were treated with a precision cryotherapy via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week. Then, they were follow up at 1 and 3 months after the last treatment. Subjective assessment of physician and patient improvement were evaluated. Moreover, Melasma Area and Severity Index (MASI), melanin and erythema index using Mexameter were also recorded.

Conditions

  • Cryotherapy Effect

Interventions

  • TargetCoolDevice

    The patients were treated with TargetCool via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change of Melasma Area and Severity Index scoreTime frame: Baseline, 1, 2, 3 weeks after the first treatment and 1, 3 months after the last treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Dermatology, Siriraj Hospital, Mahidol University

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.